. Author manuscript; available in PMC: 2014 Jul 1.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2013 May 2;33(7):1728–1733. doi: 10.1161/ATVBAHA.112.301174

Table 3.

Reclassification Matrix for CVD During 10 Years of Follow-up

Without Biomarkers	With TNFRII, CRP
	<6%	6-20%	>20%	Total
*Participants without CVD events*
<6%	1142 (94.5)	67 (5.5)	0 (0.0)	1209
6-20%	73 (7.1)	904 (88.5)	45 (4.4)	1022
>20%	0 (0.0)	41 (12.0)	302 (88.1)	343
Total	1215	1012	347	2574

*Participants with CVD events*
<6%	27 (90.0)	3 (10.0)	0 (0.0)	30
6-20%	7 (6.5)	91 (84.3)	10 (9.3)	108
>20%	0 (0.0)	9 (7.8)	106 (92.2)	115
Total	34	103	116	253

Analyses were censored at 10-year follow-up. Provided are the number of individuals and row percent. Net-reclassification improvement was −1.1%, P=0.62. Participants with prevalent major CVD were excluded from analyses of incident major CVD resulting in N=253 individuals for analysis. Green shaded cells represent favorable reclassification, red shaded cells unfavorable reclassification.